Decreased All-Cause and Liver-Related Mortality Risk in HIV/Hepatitis B Virus Coinfection Coinciding With the Introduction of Tenofovir-Containing Combination Antiretroviral Therapy
Open Access
- 25 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 7 (7), ofaa226
- https://doi.org/10.1093/ofid/ofaa226
Abstract
The development of efficacious combination antiretroviral therapy (cART) has led to a dramatic decrease in mortality in HIV-positive patients. Specific data on the impact in HIV/hepatitis B virus (HBV)–coinfected patients are lacking. In this study, all-cause and cause-specific mortality risks stratified per era of diagnosis are investigated. Data were analyzed from HIV/HBV-coinfected patients enrolled in the ATHENA cohort between January 1, 1998, and December 31, 2017. Risk for (cause-specific) mortality was calculated using Cox proportional hazard regression analysis, comparing patients diagnosed before 2003 with those diagnosed ≥2003. Risk factors for all-cause and liver-related mortality were also assessed using Cox proportional hazard regression analysis. A total of 1301 HIV/HBV-coinfected patients were included (14 882 person-years of follow-up). One-hundred ninety-eight patients (15%) died during follow-up. The adjusted hazard ratio (aHR) for all-cause mortality in patients diagnosed in or after 2003 was 0.50 (95% CI, 0.35–0.72) relative to patients diagnosed before 2003. Similar risk reduction was observed for liver-related (aHR, 0.29; 95% CI, 0.11–0.75) and AIDS-related mortality (aHR, 0.44; 95% CI, 0.22–0.87). Use of a tenofovir-containing regimen was independently associated with a reduced risk of all-cause and liver-related mortality. Prior exposure to didanosine/stavudine was strongly associated with liver-related mortality. Ten percent of the population used only lamivudine as treatment for HBV. All-cause, liver-related, and AIDS-related mortality risk in HIV/HBV-coinfected patients has markedly decreased over the years, coinciding with the introduction of tenofovir. Tenofovir-containing regimens, in absence of major contraindications, should be strongly encouraged in this population.Funding Information
- Dutch Ministry of Health
- Centre for Infectious Disease Control
- National Institute for Public Health
This publication has 24 references indexed in Scilit:
- Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infectionAIDS, 2014
- Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: Virological and clinical implicationsJournal of Hepatology, 2014
- The Coding Causes of Death in HIV (CoDe) ProjectEpidemiology, 2011
- Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B VirusGastroenterology, 2010
- Impact of Hepatitis B Virus Infection on the Progression of AIDS and Mortality in HIV‐Infected Individuals: A Cohort Study and Meta‐AnalysisClinical Infectious Diseases, 2009
- Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapyAIDS, 2006
- Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabineJournal of Hepatology, 2004
- Tenofovir Disoproxil Fumarate in Patients with HIV and Lamivudine-Resistant Hepatitis B VirusThe New England Journal of Medicine, 2003
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Fulminant Hepatic Failure Associated with 2′,3′-Dideoxyinosine (ddI)Annals of Internal Medicine, 1991